PhecdaMed
CompanyChina
PhecdaMed develops one asset, in phase 2 (TJ0113 in Parkinson's disease). Mostly small molecule acting on autophagy; based in China.
- 1
- Asset
- Furthest stage
- Phase 2
- 1
- Trial
- 0
- Signals
Pipeline
1Selective mitophagy activator
Phase 2, Small molecule, Autophagy, Parkinson's disease, sarcopenia
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials1
- Signals1
- Similar companies6